Won Hyeok Choe

Dr. Won Hyeok Choe


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2020 in Gut
Verified
Journal Article
Closed access
PDF file
MKMinseok Albert Kim
Minseok Albert Kim
Seung Up KimSeung Up Kim
Seung Up Kim
DSDong Hyun Sinn
Dong Hyun Sinn
Jeong Won JangJeong Won Jang
Jeong Won Jang
YLYoung-Suk Lim
Young-Suk Lim
JLJeong-Hoon Lee
Jeong-Hoon Lee
Objective Direct comparison of the clinical outcomes between nucleos(t)ide analogue (NA) discontinuation versus NA continuation has not been performed in patients with chronic hepatitis B who achieved HBsAg-seroclearance. Whether NA discontinuation was as safe as NA continuation after NA-induced surface antigen of HBV (HBsAg) seroclearance was investigated in the present study. Designs This multicentre study included 276 patients from 16 hospitals in Korea who achieved NA-induced HBsAg seroclearance: 131 (47.5%) discontinued NA treatment within 6 months after HBsAg seroclearance (NA discontinuation group) and 145 (52.5%) continued NA treatment (NA continuation group). Primary endpoint was HBsAg reversion and secondary endpoints included serum HBV DNA redetection and development of hepatocellular carcinoma (HCC). Results During follow-up (median=26.9 months, IQR=12.2–49.2 months), 10 patients (3.6%) experienced HBsAg reversion, 6 (2.2%) showed HBV DNA redetection and 8 (2.9%) developed HCC. Compared with NA continuation, NA discontinuation was not associated with HBsAg reversion in both univariable (HR=0.45, 95% CI=0.12 to 1.76, log-rank p=0.24) and multivariable analyses (adjusted HR=0.65, 95% CI=0.16 to 2.59, p=0.54). The cumulative probabilities of HBsAg reversion at 1, 3 and 5 years were 0.8%, 2.3% and 5.0% in the NA discontinuation group, and 1.5%, 6.3% and 8.4% in the NA continuation group, respectively. NA discontinuation was not associated with higher risk of either HBV redetection (HR=0.83, 95% CI=0.16 to 4.16, log-rank p=0.82) or HCC development (HR=0.53, 95% CI=0.12 to 2.23, log-rank p=0.38). Conclusion The discontinuation of NA was not associated with a higher risk of either HBsAg reversion, serum HBV DNA redetection or HCC development compared with NA continuation among patients who achieved HBsAg seroclearance with NA.

4 June 2008 in Liver International
Verified
Journal Article
Closed access
PDF file
WCWon Hyeok Choe
Won Hyeok Choe
SKSo Young Kwon
So Young Kwon
BKByung Kook Kim
Byung Kook Kim
SKSoon Young Ko
Soon Young Ko
JYJong Eun Yeon
Jong Eun Yeon
CLChang Hong Lee
Chang Hong Lee

7 July 2019 in World Journal of Gastroenterology
Verified
Journal Article
Open access
HPHee Sun Park
Hee Sun Park
WCWon Hyeok Choe
Won Hyeok Choe
HHHye Seung Han
Hye Seung Han
MYMi Hye Yu
Mi Hye Yu
YKYoung Jun Kim
Young Jun Kim
SKSo Young Kwon
So Young Kwon
Accurate detection of significant fibrosis (fibrosis stage 2 or higher on the METAVIR scale) is important especially for chronic hepatitis B (CHB) patients with high viral loads but with normal or mildly elevated alanine aminotransferase (ALT) levels because the presence of significant fibrosis is accepted as the indication for antiviral treatment. Liver biopsy is the reference standard for diagnosing significant fibrosis, but it is an invasive procedure. Consequently, noninvasive imaging-based measurements, such as magnetic resonance elastography (MRE) or two-dimensional shear-wave elastography (2D-SWE), have been proposed for the quantitative assessment of liver fibrosis. To explore MRE and 2D-SWE to identify fibrosis stage, and to compare their performance with that of serum-based indices. The study enrolled 63 treatment-naïve CHB patients with high viral loads but with normal or mildly elevated ALT levels who underwent liver biopsy before a decision was made to initiate antiviral therapy. MRE and 2D-SWE were performed, and serum-based indices, such as FIB-4 and aspartate transaminase to platelet ratio index (APRI), were calculated. The diagnostic performances of MRE, 2D-SWE, FIB-4, and APRI for assessing significant fibrosis (≥ F2) and cirrhosis (F4) were evaluated with liver histology as the reference standard, using receiver operating characteristic analyses. The liver fibrosis stage was F0/F1 in 19, F2 in 14, F3 in 14, and F4 in 16 patients, respectively. MRE significantly discriminated F2 from F0/1 (P = 0.022), whereas 2D-SWE showed a broad overlap in distinguishing those stages. MRE showed a higher correlation coefficient value with fibrosis stage than 2D-SWE with fibrosis stage (0.869 vs 0.649, Spearman test; P < 0.001). Multivariate linear regression analyses showed that fibrosis stage was the only factor affecting the values of MRE (P < 0.001), whereas body mass index (P = 0.042) and fibrosis stage (P < 0.001) were independent factors affecting 2D-SWE values. MRE performance for diagnosing significant fibrosis was better [area under the curve (AUC) = 0.906, positive predictive value (PPV) 97.3%, negative predictive value (NPV) 69.2%] than that of FIB-4 (AUC = 0.697, P = 0.002) and APRI (AUC = 0.717, P = 0.010), whereas the performance of 2D-SWE (AUC = 0.843, PPV 86%, NPV 65%) was not significantly different from that of FIB-4 or APRI. Compared to SWE, MRE might be more precise non-invasive assessment for depicting significant fibrosis and for making-decision to initiate antiviral-therapy in treatment-naïve CHB patients with normal or mildly-elevated ALT levels.

31 August 2012 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
SKSoon Young Ko
Soon Young Ko
WCWon Hyeok Choe
Won Hyeok Choe
SKSo Young Kwon
So Young Kwon
JKJeong Han Kim
Jeong Han Kim
JSJung Woong Seo
Jung Woong Seo
CLChang Hong Lee
Chang Hong Lee
Objective. Partial virologic response (PVR) in chronic hepatitis B (CHB) patients during antiviral therapy is associated with an increased risk of occurrence of viral resistance and treatment failure. The aim of this study was to evaluate the clinical and virological responses of partial responders to long-term entecavir (ETV) monotherapy. Material and method. In this open-labeled prospective study, 128 treatment-naïve CHB patients treated with 0.5 mg ETV once daily for more than 12 months were monitored at baseline and at 3-month intervals during treatment. Results. At baseline, the mean age of subjects was 47.0 ± 13.0 years, and the median duration of treatment was 27 months; 85 subjects (66.4%) were HBeAg-positive, and 47 patients (36.7%) had liver cirrhosis. Eighteen of 128 patients (14.0%) showed PVR to 48 weeks of ETV treatment, and 13 patients were followed up for over 24 months. Among them, 9 of 13 patients (69.2 %) achieved a complete virologic response (VR, HBV-DNA < 60 IU/mL) during prolonged ETV treatment. Four showed persistent PVR, but only one patient with poor compliance developed genetic resistance to ETV at month 27. The occurrence of PVR was independently associated with a high viral load, more than 7 log10 IU/mL (p = 0.014). Conclusions. CHB patients with a high viral load, more than 7 log log10 IU/mL, are related to the occurrence of PVR during ETV monotherapy. Long-term ETV monotherapy may be effective for suppressing serum HBV DNA levels in treatment- naïve CHB patients with a PVR to ETV.

21 February 2013 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
JKJa Kyung Koo
Ja Kyung Koo
JKJeong Han Kim
Jeong Han Kim
YCYun Jung Choi
Yun Jung Choi
CLCho I Lee
Cho I Lee
JYJae Hoon Yang
Jae Hoon Yang
CLChang Hong Lee
Chang Hong Lee

1 March 2022 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
Mina HurMina Hur
Mina Hur
MPMikyoung Park
Mikyoung Park
HMHee-Won Moon
Hee-Won Moon
WCWon Hyeok Choe
Won Hyeok Choe
CLChae Hoon Lee
Chae Hoon Lee
Mina Hur, M.D., Ph.D., Mikyoung Park, M.D., Ph.D., Hee-Won Moon, M.D., Ph.D., Won Hyeok Choe, M.D., Ph.D., and Chae Hoon Lee, M.D., Ph.D.. Ann Lab Med 2022;42:249-57. https://doi.org/10.3343/alm.2022.42.2.249